申请人:VERTEX PHARMACEUTICALS INCORPORATED
公开号:EP2361925A1
公开(公告)日:2011-08-31
The present invention relates to compounds of formula: (I) or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing theses compounds.
本发明涉及能抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒 NS3-NS4A 蛋白酶活性的式:(I)或其药学上可接受的盐或混合物,它们能抑制丝氨酸蛋白酶的活性,特别是丙型肝炎病毒 NS3-NS4A 蛋白酶的活性。因此,它们通过干扰丙型肝炎病毒的生命周期发挥作用,也可用作抗病毒药物。本发明还涉及包含这些化合物的组合物,这些组合物可用于体内外使用,也可用于丙型肝炎病毒感染患者,还涉及制备这些化合物的工艺。本发明还涉及通过施用包含本发明化合物的组合物治疗患者 HCV 感染的方法。本发明还涉及制备这些化合物的工艺。